Product Description
CPB506 is a 1+1 bivalent bispecific checkpoint inhibitor antibody designed to target mouse lymphocyte-activation gene 3 (LAG3) and mouse cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CPB506 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity. CTLA-4 blockade reduces competition with CD28 for CD80/CD86, enhancing costimulatory signaling and promoting expansion and priming of effector T cells. LAG-3 is upregulated on chronically stimulated T cells and many intratumoral Tregs, where it dampens TCR signaling and contributes to exhaustion and reduced cytokine production. CPB506 is designed to simultaneously block two distinct inhibitory receptors and enrich bispecific concentration and potency to dual-positive cells in the tumor microenvironment to reinvigorate dysfunctional T cells and enhance antitumor T-cell responses while limiting systemic toxicity.
* VAT and shipping costs not included. Errors and price changes excepted
